Skip to main content
British Medical Journal logoLink to British Medical Journal
letter
. 1969 Mar 29;1(5647):822–824. doi: 10.1136/bmj.1.5647.822

Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and Lymphosarcoma

K Hellmann, K A Newton, D N Whitmore, I W F Hanham, Jane V Bond
PMCID: PMC1982474  PMID: 5251696

Abstract

I.C.R.F. 159, a new antitumour agent, has been assessed in six patients with acute leukaemia and three with lymphosarcoma. In all but two there was a considerable fall in circulating primitive cells, and in one there was bone-marrow evidence of a partial remission. Severe toxic effects were seen in only one case; they consisted of alopecia and gastroenteritis. It is suggested that I.C.R.F. 159 is worth further examination in all forms of acute leukaemia and lymphosarcoma.

Full text

PDF
822

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES